Newsroom | 28173 results

TORONTO, Ontario--(BUSINESS WIRE)--Celltrion, Inc. today announced that Health Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea.1 “Today’s approval lays a solid foundation for Celltrion’s expansion into the Canadian ophthalmology market and represents a significant milestone in diversifying the company’s portfolio,” said Jungyong Shin, Managing Director at Celltrion...

TORONTO, Ontario--(BUSINESS WIRE)--Celltrion, Inc. annoncé aujourd'hui que Santé Canada a approuvé l'Eydenzelt®, un biosimilaire référençant l'Eylea® (aflibercept 2mg), en flacon et en seringue préremplie, pour le traitement de toutes les indications approuvées pour l'Eylea.1 « L’approbation d’aujourd’hui jette des bases solides pour l’expansion de Celltrion sur le marché canadien de l’ophtalmologie et représente une étape importante dans la diversification du portefeuille de la société », décl...

INCHEON, Corea del Sud--(BUSINESS WIRE)--La Commissione Europea (CE) ha approvato l'estensione di linea nell'Unione Europea (UE) per Omlyclo™ (omalizumab) di Celltrion, il primo e unico biosimilare di omalizumab in Europa, per la siringa preriempita (PFS) da 300 mg/2ml. La Commissione Europea (CE) ha approvato la soluzione iniettabile di Omlyclo™ da 75 mg/0,5ml e 150mg/1ml in siringa preriempita nel maggio 2024. Omlyclo™ è indicato nel trattamento di pazienti affetti da asma allergica, orticari...

MANHASSET, N.Y.--(BUSINESS WIRE)--Recent reports show that one in seven first responders have probable post-traumatic stress disorder (PTSD) in response to routine duties with prevalence increasing after responding to a crisis. To improve our understanding and the well-being of these essential heroes, researchers at Northwell Health’s Feinstein Institutes for Medical Research, Stony Brook University and Texas A&M University received a $3.37-million grant from the National Institute of Menta...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today that it has received FDA Premarket Authorization for Pristina Recon DL, an advanced 3D mammography image reconstruction technology. Powered by deep learning, Pristina Recon DL sets a new standard in image definition and sharpness. Breast cancer remains one of the most common cancers among women, with one in eight expected to face a diagnosis in their lifetime2 and an estimated 1.1 million breast cancer–related deaths project...

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), världens ledande kvantdatorföretag, tillkännagav idag utnämningen av fil.dr Marco Pistoia, till Chief Executive Officer för IonQ Italia S.r.l., ett helägt dottebolag. Dr Pistoia kommer att leda IonQ:s strategiska initiativ i Italien och bygga vidare på företagets ställning som världens enda heltäckande kvantplattform med produkter och tjänster för kvantdatorer, kvantnätverk, kvantanalys och kvantsäkerhet. IonQ Italia kommer att hjälpa Itali...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 8th Annual Evercore Healthcare Conference Date/Time: Wednesday, Dec. 3, 2025 at 2:10 p.m. ET (7:10 p.m. GMT) Piper Sandler 37th Annual Healthcare Conference Date/Time: Thursday, Dec. 4, 2025 at 12:00 p.m. ET (5:00 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alke...

BOSTON--(BUSINESS WIRE)--Computer vision startup Ubicept announces the release of the Ubicept Toolkit, which brings its physics-based imaging to any modern vision system....

TORONTO & NEW YORK--(BUSINESS WIRE)--Survey finds 65% of pharma marketers distrust AI for compliance submissions, underscores need for glass-box AI with audit trails and explainability...

SAN MATEO, Calif.--(BUSINESS WIRE)--New clearances expand the Rapid Enterprise Platform, advancing radiology precision, and elevating neurology and vascular care through deep clinical AI...